electroCore (NASDAQ:ECOR) Interim President and CFO Joshua Lev said the bioelectronic technology company is focused on expanding its non-invasive vagus nerve stimulation platform across federal health care, commercial insurance channels and consumer wellness markets.
Speaking at the LD Micro event, Lev said electroCore has grown revenue at a compound annual rate of more than 50% over the past five years and reported $32 million in full-year 2025 revenue. He said the company’s gross profit margin has improved from the low 70% range to 87% in the first quarter of 2026.
